and sulfate-conjugates are also hydrolyzed by the corresponding enzymes from various intestinal bacterial sources. Deconjugated compounds are absorbed via portal vein and conjugated again in liver. Some drugs are retained in the body for a long period of time through such enterohepatic circulation, which is beneficial in long-term therapeutic effect, but may cause a chronic side-effect, for example, induction of drug-metabolizing enzymes. No ureases are detected in germ-free animals and hydrolysis of urea that occurred in the bodies is responsible for the enzymes from intestinal, or infected microorganisms.
Reductive reactions are also predominant in intestinal flora because of strictly anaerobic conditions, especially in a lower part of intestine. Various enzymes reducing azo-and nitro-group to amino-group, and keto-and aldehyde-group to hydroxyl-group are well known. Double bonds of bilirubin, cinnamic acid, magnolol etc. are reduced and 7a-hydroxyl groups of primary bile acids are reduced to secondary bile acids by the corresponding bacteria and enzymes.
Lyases are enzymes cleaving C-C, C-N and other bonds excepting hydrolytic cleavage, but intestinal bacterial lyases have not been clarified. Amino acid decarboxylases which catalyze the formation of histamine, tyramine, putrescine, agmatine and so on are well established. Among transferases, adenylation reaction and N-acetylation cause several antibiotics to be ineffective.
We have been studying on the metabolism of drugs, mainly major constituents present in the oriental crude drugs, by human intestinal flora for decades. Through the investigation, we isolated bacterial strains responsible for the respective metabolic processes and purified the responsible enzymes from the bacteria. Such drugmetabolizing enzymes happened to lead to the discovery of new types of reaction and novel types of enzyme. Moreover, many metabolites are new compounds and are pharmacologically more effective than the original drugs. In other words, the intestinal bacterial enzymes activate drugs (prodrug) to genuine principles. We describe the summary of several examples of drug metabolism with intestinal bacteria and their responsible enzymes, which were performed in our laboratory, in the following chapters. ACTIVATION OF PICOSULFATE
BY BACTERIAL SULFOTRANSFERASE
Picosulfate, 4,4'-(2-pyridinylmethylene)-bisphenol bis (hydrogen sulfate) (ester), is used as a laxative at present. Its effect is slowly exhibited after oral administration and is lost by the simultaneous administration of antibiotics, suggesting that the intestinal bacteria play the necessary role in the manifestation of the pharmacological effect; the drug itself is inactive as a laxative, but the desulfated compounds, chemically similar to phenolphthalein, is produced by human intestinal bacteria, and cause a laxative effect (26) . This activation process is not a hydrolytic reaction, but a sulfate-transfer reaction requiring a phenolic acceptor such as tyramine as shown in Fig. 1 . The novel arylsulfotransferase is purified from Eubacterium A-44, isolated from human feces, and catalyzes the transfer of sulfate group of a sulfated phenolic compound to another phenolic compound (25 , 27) . Th e properties of the enzyme are summarized in Fig . 2 . The bacterial enzyme is characteristic of the requirement of the sulfated phenolic compounds as the donor substrate, different from that of 3'-phosphoadenosine-5'-phosphosulfate as the donor Table 2 . Arylsulfotransferase and arylsulfatase activities in human and rat feces in animal enzymes, and of the specific activity 1,000-fold higher than that of animal enzymes. The bacterial enzyme is beneficial for the sulfation of phenolic compounds and of tyrosine-containing peptides, which are difficult chemically to synthesize (29) . Furthermore, it is of interest that the arylsulfotransferase activities are higher in human feces than in rat feces, compatible with less effect as the laxative of picosulfate in rats than in human, and are higher than sulfatase activity in human and rat feces ( Most of human intestinal bacterial strains can reduce sennidins to rhein anthrone. Among them Peptostreptococcus intermedius has higher activity to reduce sennidins and sennosides, which is stimulated by the addition of FAD, NADH and glucose (Table 6 ) and is inhibited with oxygen. We isolated an enzyme from P. intermedius which takes part in the reductive cleavage of bianthrones to the monomeric units (7) . This enzyme catalyzes the electron transfer from NADH to FAD, FMN or benzyl viologen, which reduce non-enzymatically sennosides and sennidins to 8-glucosyl-rhein anthrone and rhein anthrone, respectively (Fig. 5) (8) . In this reaction, sennidins are more readily cleaved to their monomeric units than sennosides, due to that the former possesses higher redox potential than the latter. The isolation of this enzyme from the dominant bacterium in the human intestine strongly supports the presence of the two metabolic pathways. Since sennidins are reduced much faster than sennosides by reduced forms of the cofactors , enzymatic hydrolysis of sennosides to the aglycone (pathway I) may be more predominant in gut than reductive cleavage of sennosides to 8-glucosyl-rhein anthrone (pathway II) (16) . Geniposide is a major iridoid glucoside in the fruit of Gardenia jasminoides (Rubiaceae) which is widely used as an antiphlogistic and cholagogue in traditional Chinese medicine. This compound has choleretic action when administered orally, Fig. 7 
METABOLISM OF BARBALOIN BY C-GLUCOSIDASE
Barbaloin is a popular laxative from aloe, but less purgative than sennosides. Similar to the case of sennosides, an anthrone derivative, an aglycone of barbaloin, was considered to be the ultimate purgative of barbaloin, but any evidence that barbaloin is transformed to aloe-emodin anthrone by intestinal bacteria has not been observed hitherto. Barbaloin is C-glycoside, special type of glycosides since C-1 of the sugar ring is directly attached to the aglycone nucleus by a C-C bond. The C-C bond is resistant toward acid and enzymic hydrolysis in contrast with O -glycosides . However, we recently found that barbaloin is metabolized to aloeemodin anthrone by anaerobic incubation with a bacterial mixture from human feces (14) . This transformation includes a unique type of cleavage of the C-glucosyl bond (Fig. 8) . On the contrary, bacterial mixtures from rat and mouse feces, and 23 defined strains of human intestinal bacteria do not metabolize barbaloin to aloe-emodin anthrone, this observation being in agreement with that barbaloin hardly induces a purgative action in rats and mice but readily induces it in humans .
In the line of studies on the metabolism of barbaloin, we isolated a bacterium, named Eubacterium strain BAR, capable of metabolizing barbaloin to aloe-emodin anthrone from human feces (9) . Eubacterium sp. strain BAR transforms barbaloin to aloe-emodin anthrone in a basal medium lacking carbohydrate (11). Barbaloin in the culture medium, suggesting the induction of the enzyme is repressed with glucose. Though nojilimycin bisulfite, an inhibitor of glucosidase, does not affect the growth with glucose or cellobiose, it inhibits not only the growth with barbaloin, but also the transformation of barbaloin to aloe-emodin anthrone. These findings suggest that a unique enzyme capable of cleaving the C-glucosyl bond is C-glucosidase, but not O-glucosidase. Other C-glycosides are known to occur in plant, such as flavonoid C-glycosides, xanthone C-glycosides, chromone C-glycosides, anthrone C-glycosides and Cglycosylated gallic acids. Homoorientin, a C-glucosylflavonoid, is obtained from a whole plant of Swertia japonica. Mangiferin is a xanthone C-glucoside distributed widely in the plant kingdoms. Similarly, bergenin, C-glucosylated gallic acid, is isolated from Astlbe thunbergii. Aloesin and aloeresin A are chromone C-glucosides present in aloe. By anaerobic incubation with a bacterial mixture from human feces, C-C bonds of these C-glucosides are also cleaved to form the corresponding aglycones ( Fig. 9) (10, 19, 22) .
Through the investigations on drug metabolism with human intestinal bacteria, we found that many drugs and naturally occurring substances are transformed to new various metabolites in gut, among which some metabolites exhibit pharmacological activities. In other words, some drugs are considered to be natural prodrugs, which are converted to genuine active compounds by intestinal bacteria. During the course of experiments, we discovered several new types of enzymes relating drug metabolism from intestinal bacterial strains, which is a treasure house of novel enzymes. We also observed some variations in the metabolic activities and in the amount of the metabolites among the fecal specimens from different subjects. No significant change was observed in the same subjects in the repeated experiments. Some variations in the drug metabolism may occur depending upon the different population and species of intestinal bacteria in different individuals, probably due to the responsible metabolic enzyme activity. In this review, we described only the summary of our previous reports on drug metabolism with intestinal flora, which is a wide, but unknown field of biochemistry and is expected to be developed in the coming future. 
